India Glycols Q2 FY27 profit falls 27.3% sequentially

India Glycols Limited reported Q2 FY27 consolidated revenue of ₹362.42 crore and net profit of ₹23.69 crore, with profit declining 27.3% sequentially despite a 1.5% sequential increase in revenue. The results matter because the company is reporting after a demerger that makes year-on-year comparisons not comparable.

What did India Glycols report for Q2 FY27?

India Glycols Limited, or IGL, reported unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved the standalone and consolidated results at its meeting on November 13, 2026.

On a consolidated basis, IGL's Q2 FY27 revenue was ₹362.42 crore, up 1.5% from the previous quarter. Consolidated net profit was ₹23.69 crore, down 27.3% sequentially, while the EBITDA margin stood at 9.7%. The detailed results disclosure separately recorded total income of ₹362.75 crore and profit before tax of ₹15.06 crore for the quarter.

The company reported no exceptional items in the quarter. Its statutory auditors, K.N. Gutgutia & Co., completed a limited review and issued an unmodified conclusion dated November 13, 2026.

How did IGL's standalone business perform?

IGL reported standalone revenue of ₹358.18 crore in Q2 FY27, representing a 1.0% sequential increase. Standalone EBITDA margin was 11.0%, above the consolidated margin of 9.7% reported in the results summary.

Standalone net profit was ₹11.24 crore, down 9.0% sequentially. The company's detailed standalone statement showed total income of ₹358.51 crore and profit before tax of ₹15.25 crore for the September quarter.

For the six months ended September 30, 2026, standalone total income from operations was ₹713.52 crore. Standalone profit before tax for the half-year stood at ₹31.79 crore. These figures cover the period following the accounting effects of the approved scheme of arrangement.

The company identified Bio-based Specialties and Performance Chemicals as its single reportable segment. Standalone segment revenue for H1 FY27 was ₹712.82 crore, closely aligned with total income from operations for the same period.

Why are year-on-year comparisons not comparable?

Year-on-year comparison is not comparable because IGL's reported figures reflect a Scheme of Arrangement involving the demerger of its Spirits and Biofuel Undertaking and Biopharma Undertaking. The company specifically noted that the demerger affects comparative financial figures.

This means investors should avoid treating current-period movement against earlier reported periods as a like-for-like operating trend without reviewing the restated or adjusted comparative information in the financial statements. The reported sequential changes offer a more direct comparison within the post-demerger reporting structure, though they also need to be read alongside the notes to the accounts.

The scheme was approved by the National Company Law Tribunal, according to the results disclosure. Its inclusion in the financial statements signals that the company's reported standalone and consolidated profiles have changed from the pre-demerger structure.

For H1 FY27, consolidated total income from operations was reported at ₹4,919.09 crore and consolidated profit before tax at ₹64.48 crore. Consolidated segment revenue was ₹4,915.52 crore. These disclosed half-year figures should be considered with the scheme-related adjustments noted by the company.

What does the Q2 result mean for investors and operations?

The Q2 result shows that IGL achieved modest sequential revenue growth while consolidated profit declined more sharply. A 1.5% increase in consolidated revenue was accompanied by a 27.3% fall in net profit, while the standalone business recorded a 1.0% revenue increase and a 9.0% decline in net profit.

The difference between revenue movement and profit movement makes margins and costs important areas for investors to assess. The company reported a 9.7% consolidated EBITDA margin and an 11.0% standalone EBITDA margin, but the release did not provide a detailed explanation for the sequential movement in net profit.

The absence of exceptional items means the quarter's reported earnings were not affected by separately identified exceptional gains or charges. However, that does not by itself explain all changes in profitability, particularly because the demerger has altered the basis for historical comparisons.

The unmodified limited-review conclusion provides confirmation that the auditors did not modify their conclusion on the unaudited results. It is not an audit opinion, but it is a relevant disclosure for shareholders reviewing the quarterly financial statements.

What are the next disclosed events for IGL investors?

IGL has scheduled an earnings conference call for November 18, 2026, at 16:00 IST to discuss its Q2 and H1 FY27 performance. The company said the call will include CEO Rupark Sarswat, CFO Anand Singhal, Head of Legal Ankur Jain, and Investor Relations head Gagan Kwatra.

The call is the next disclosed forum for management to discuss the results and outlook. Investors may seek more clarity on the sequential profit decline, the impact of the demerger on comparability, and the operating drivers behind the reported margins.

The Board meeting that approved the results was held on November 13, 2026, after the company had informed exchanges on November 6 that it would consider the unaudited standalone and consolidated statements. The timing places the results 44 days after the September quarter-end.

The company previously reported Q1 FY27 results on August 12, 2026. But because the current release states that the demerger affects comparative figures, trend assessment should be anchored in the financial statement notes and management's explanations rather than relying only on headline growth rates.

Conclusion

IGL's Q2 FY27 disclosure shows a quarter of modest sequential revenue growth and lower profit. Consolidated revenue rose 1.5% to ₹362.42 crore, while net profit fell 27.3% to ₹23.69 crore; standalone revenue increased 1.0% and standalone net profit declined 9.0%. The company also reported no exceptional items and an unmodified limited-review conclusion.

The key event to watch is IGL's November 18, 2026 earnings call, when management is scheduled to discuss Q2 and H1 FY27 performance. Investors will be looking for management's comments on margins, the reasons for the sequential profit movement, and the continuing effect of the approved demerger on financial comparability.